Investors

Media

Welcome to the new Regeneron Newsroom. This newsroom is designed to provide members of the media with easy access to up-to-date information about the Company.

For an e-mail response to questions about Regeneron, please contact us at media@regeneron.com.



Upcoming Events

Oct 1, 2016
7:00 AM ET
Webcast IR Thematic call on dupilumab in atopic dermatitis: EADV 2016


View all releases Recent Press Releases

Sep 30, 2016 Regeneron Announces Phase 2 Study of Aflibercept Co-Formulated with Rinucumab (anti-PDGFR-beta) Shows No Benefit Over Aflibercept Alone in Neovascular Age-Related Macular Degeneration
Sep 26, 2016 Regeneron and Sanofi Announce Dupilumab Biologics License Application Accepted for Priority Review by U.S. FDA
Sep 20, 2016 Regeneron and Teva Announce Global Collaboration to Develop and Commercialize Fasinumab, an Investigational NGF Antibody for Chronic Pain
Sep 12, 2016 Regeneron Announces Election of Bonnie Bassler, Ph.D., and Huda Zoghbi, M.D., to Board of Directors
Sep 1, 2016 Regeneron Announces Upcoming 2016 Investor Conference Presentations
Aug 29, 2016 Regeneron and Sanofi Present Positive Phase 3 Investigational Data for Praluent® (alirocumab) Injection in Patients Undergoing LDL Apheresis Therapy at ESC Congress 2016
Aug 22, 2016 Regeneron Announces Agreement with BARDA for the Manufacturing and Testing of New Antibodies Against MERS Virus
Aug 4, 2016 Regeneron Reports Second Quarter 2016 Financial and Operating Results
Aug 2, 2016 Regeneron and Adicet Bio Announce Strategic Collaboration to Discover and Develop Next-Generation Engineered Immune Cell Therapeutics
Jul 18, 2016 Regeneron Announces Upcoming 2016 Investor Conference Presentation


Close
Form content here please :)